P/E at 31.35 vs Industry's 37.76: What the Data Shows for Dr Reddys Laboratories Ltd

1 hour ago

Share Via

A price-to-earnings ratio of 31.35 against an industry average of 37.76 reveals a notable valuation discount for Dr Reddys Laboratories Ltd. Previously rated Hold by MarketsMojo, the stock’s rating was reassessed on 13 Jul 2026. While the one-year return of -7.25% slightly outperforms the Sensex’s -9.16%, the three-month performance shows a sharper decline of -9.29%, underperforming the broader market. The data paints a nuanced picture of valuation and momentum tension.

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 31.35, which is approximately 17% below the Pharmaceuticals & Biotechnology industry average of 37.76. This discount suggests that the market is pricing in either a relative earnings risk or slower growth prospects compared to peers. Given the sector’s elevated valuation, the stock’s lower P/E could be interpreted as a cautious stance by investors, especially considering the recent performance trends. Previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating? This valuation gap invites scrutiny of the underlying fundamentals and market sentiment.

Performance Across Timeframes: Divergent Momentum

Examining the stock’s returns reveals a complex momentum profile. Over the past year, Dr Reddys Laboratories Ltd has declined by 7.25%, modestly outperforming the Sensex’s 9.16% fall. This relative resilience is further emphasised by the year-to-date return of -5.20%, which is significantly better than the Sensex’s -12.90%. However, the short-term picture is less encouraging. The three-month return of -9.29% lags the Sensex’s -3.59%, indicating recent weakness. The one-month and one-week returns of 0.88% and 2.81% respectively show some recovery attempts, but the three-month slide raises questions about the sustainability of this bounce — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Mixed Technical Signals

The technical setup of Dr Reddys Laboratories Ltd further illustrates the stock’s current state. It trades above its 5-day, 20-day, and 50-day moving averages, signalling short-term strength and a possible bounce from recent lows. However, it remains below the 100-day and 200-day moving averages, which typically represent longer-term trend resistance. This configuration suggests the stock is in a recovery phase within a broader downtrend, a pattern often seen in stocks attempting to regain footing after a correction. The 5% surge partially reverses a 6.45% monthly decline — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Relative Performance Versus Sensex

When compared to the Sensex, Dr Reddys Laboratories Ltd has demonstrated mixed relative strength. Its one-day performance of -0.42% outperformed the Sensex’s -0.80%, and over one week, it gained 2.81% while the Sensex declined marginally by 0.11%. The one-month return of 0.88% also contrasts favourably with the Sensex’s 4.06% loss. However, the three-month underperformance of -9.29% versus the Sensex’s -3.59% highlights recent challenges. Over longer horizons, the stock’s five-year return of 25.71% slightly surpasses the Sensex’s 23.62%, but the ten-year return of 89.40% lags the Sensex’s 158.93%, indicating a slower growth trajectory over the decade. This relative performance divergence raises the question — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen 28 stocks declare results recently, with 13 reporting positive outcomes, 11 flat, and 4 negative. This distribution suggests a broadly stable sector environment with pockets of strength and weakness. Dr Reddys Laboratories Ltd operates within this mixed backdrop, which may be influencing its valuation and performance. The sector’s average P/E of 37.76 reflects investor willingness to pay a premium for growth and innovation, yet why does Dr Reddys trade at a discount to this benchmark? The answer may lie in recent earnings trends or market sentiment shifts.

Rating Reassessment: From Hold to a New Status

On 13 Jul 2026, the rating for Dr Reddys Laboratories Ltd was updated from Hold to a different grade, reflecting a reassessment of its fundamentals and market position. The Mojo Score currently stands at 36.0, indicating a cautious stance. This change aligns with the valuation discount and recent performance trends, signalling a more conservative outlook. What does this updated rating imply for investors evaluating the stock now?

Conclusion: A Complex Valuation and Momentum Landscape

The data on Dr Reddys Laboratories Ltd reveals a stock trading at a meaningful discount to its sector’s P/E, with a mixed performance profile that combines relative resilience over one year with recent short-term weakness. The moving average configuration suggests a tentative recovery within a longer-term downtrend, while sector results remain mixed. The rating update from Hold to a more cautious grade reflects these complexities. Collectively, these factors underscore the importance of weighing valuation against momentum and sector dynamics — should investors reconsider their stance on Dr Reddys Laboratories Ltd?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE